Lanreotide vs Pasireotide
Overview
Lanreotide and Pasireotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Lanreotide and Pasireotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Lanreotide | Pasireotide | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 60-120 mg | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) |
| Frequency | every 4 weeks | Twice daily (SC formulation) or every 4 weeks (LAR formulation) |
| Reported benefits | suppression of excess growth hormone and IGF-1 in acromegaly, improved progression-free survival in GEP-NETs, reduction of carcinoid syndrome symptoms, inhibition of multiple GI and pancreatic hormones | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism |
| Reported side effects | diarrhea, cholelithiasis, abdominal pain, hyperglycemia, bradycardia, injection site reactions, nausea, hypertension, headache, thyroid function decreases | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) |
Key differences
Primary use. Lanreotide is categorised under Hormonal, while Pasireotide falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Lanreotide: FDA-approved. Pasireotide: FDA-approved.
Dosing. Lanreotide is typically dosed at 60-120 mg (every 4 weeks). Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)).
Can you stack them?
Some protocols combine peptides, but stacking Lanreotide and Pasireotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Lanreotide and Pasireotide?
- Lanreotide and Pasireotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. Lanreotide is FDA-approved for one or more indications, whereas Pasireotide is FDA-approved for one or more indications.
- What is Lanreotide used for?
- FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- Can you take Lanreotide and Pasireotide together?
- Some users combine peptides within a single protocol, but stacking Lanreotide and Pasireotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Lanreotide or Pasireotide FDA-approved?
- Lanreotide is FDA-approved for one or more indications. Pasireotide is FDA-approved for one or more indications.
Read the full articles
- Lanreotide — full monograph: mechanism, research, dosing & references
- Pasireotide — full monograph: mechanism, research, dosing & references